| $385M | ||
| $215M | ||
| $94M | ||
| $82M | ||
| $62M | ||
| $60M |
Buys | $349,999,986 | 1 | 4 |
Sells | $2,965,374 | 22 | 96 |
| Roivant Sciences Ltd. | 1 | $350M | 0 | $0 | $350M | |
| Macias William L. | Chief Medical Officer | 0 | $0 | 1 | $42,867 | $-42,867 |
| Barnett Eva Renee | Chief Financial Officer | 0 | $0 | 2 | $103,266 | $-103,266 |
| Geffner Michael | Chief Medical Officer | 0 | $0 | 5 | $181,440 | $-181,440 |
| Stout Jay S | Chief Technology Officer | 0 | $0 | 6 | $215,099 | $-215,099 |
| Van Tuyl Christopher | Chief Legal Officer | 0 | $0 | 1 | $290,943 | $-290,943 |
| Gloria Melanie | Chief Operating Officer | 0 | $0 | 1 | $298,237 | $-298,237 |
| Hughes Douglas J. | director | 0 | $0 | 1 | $348,665 | $-348,665 |
| Fromkin Andrew J. | director | 0 | $0 | 2 | $673,958 | $-673,958 |
| Salzmann Peter | Chief Executive Officer | 0 | $0 | 3 | $810,898 | $-810,898 |
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Over the last 12 months, insiders at Immunovant, Inc. have bought $350M and sold $2.97M worth of Immunovant, Inc. stock.
On average, over the past 5 years, insiders at Immunovant, Inc. have bought $150.61M and sold $5.53M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Roivant Sciences Ltd. () — $350M.
The last purchase of 16,666,666 shares for transaction amount of $350M was made by Roivant Sciences Ltd. () on 2025‑12‑12.
| 2026-01-07 | Sale | Stout Jay S | Chief Technology Officer | 1,203 0.0007% | $26.53 | $31,914 | -2.06% | |
| 2025-12-18 | Sale | Van Tuyl Christopher | Chief Legal Officer | 10,813 0.0063% | $26.91 | $290,943 | -0.08% | |
| 2025-12-12 | Roivant Sciences Ltd. | 16.67M 7.5524% | $21.00 | $350M | -0.91% | |||
| 2025-12-01 | Sale | Hughes Douglas J. | director | 15,000 0.0087% | $23.24 | $348,665 | +14.29% | |
| 2025-12-01 | Sale | Fromkin Andrew J. | director | 22,249 0.013% | $23.25 | $517,189 | +14.29% | |
| 2025-11-20 | Sale | Gloria Melanie | Chief Operating Officer | 12,626 0.0075% | $23.62 | $298,237 | +13.45% | |
| 2025-10-08 | Sale | Geffner Michael | Chief Medical Officer | 1,272 0.0007% | $16.30 | $20,734 | +47.33% | |
| 2025-10-08 | Sale | Stout Jay S | Chief Technology Officer | 1,585 0.0009% | $16.30 | $25,836 | +47.33% | |
| 2025-07-23 | Sale | Geffner Michael | Chief Medical Officer | 2,385 0.0014% | $18.15 | $43,288 | +1.90% | |
| 2025-07-23 | Sale | Stout Jay S | Chief Technology Officer | 2,805 0.0016% | $18.15 | $50,911 | +1.90% | |
| 2025-07-09 | Sale | Geffner Michael | Chief Medical Officer | 1,160 0.0007% | $17.24 | $19,998 | +4.86% | |
| 2025-07-09 | Sale | Stout Jay S | Chief Technology Officer | 1,519 0.0009% | $17.24 | $26,188 | +4.86% | |
| 2025-04-23 | Sale | Geffner Michael | Chief Medical Officer | 2,349 0.0014% | $14.79 | $34,742 | +15.57% | |
| 2025-04-23 | Sale | Stout Jay S | Chief Technology Officer | 1,925 0.0012% | $14.79 | $28,471 | +15.57% | |
| 2025-04-16 | Sale | Salzmann Peter | Chief Executive Officer | 8,321 0.0051% | $14.89 | $123,900 | +11.99% | |
| 2025-04-16 | Sale | Barnett Eva Renee | Chief Financial Officer | 2,993 0.0018% | $14.89 | $44,566 | +11.99% | |
| 2025-04-09 | Sale | Salzmann Peter | Chief Executive Officer | 28,094 0.0149% | $12.99 | $364,941 | +10.50% | |
| 2025-03-07 | Sale | Fromkin Andrew J. | director | 8,000 0.0047% | $19.60 | $156,769 | -16.58% | |
| 2025-02-19 | Sale | Salzmann Peter | Chief Executive Officer | 15,439 0.0091% | $20.86 | $322,058 | -19.26% | |
| 2025-02-19 | Sale | Macias William L. | Chief Medical Officer | 2,055 0.0012% | $20.86 | $42,867 | -19.26% |
| Roivant Sciences Ltd. | 113317007 56.2433% | $2.98B | 7 | 0 | +21.17% | |
| Salzmann Peter | Chief Executive Officer | 1178191 0.5848% | $30.95M | 0 | 32 | |
| Barnett Eva Renee | Chief Financial Officer | 396774 0.1969% | $10.42M | 0 | 23 | |
| Macias William L. | Chief Medical Officer | 357353 0.1774% | $9.39M | 0 | 21 | |
| Geffner Michael | Chief Medical Officer | 220553 0.1095% | $5.79M | 0 | 9 | |
| Stout Jay S | Chief Technology Officer | 199611 0.0991% | $5.24M | 0 | 9 | |
| Gloria Melanie | Chief Operating Officer | 173511 0.0861% | $4.56M | 0 | 1 | |
| Van Tuyl Christopher | Chief Legal Officer | 149930 0.0744% | $3.94M | 0 | 1 | |
| Hughes Douglas J. | director | 120773 0.0599% | $3.17M | 1 | 2 | <0.0001% |
| Fromkin Andrew J. | director | 85852 0.0426% | $2.26M | 1 | 3 | <0.0001% |
| WONG RODERICK | Chief Executive Officer | 902498 0.4479% | $23.71M | 22 | 0 | +118.39% |
| Butchko Julia G. | Chief Development Officer | 440959 0.2189% | $11.58M | 1 | 22 | <0.0001% |
| Levine Mark S. | Chief Legal Officer | 319228 0.1584% | $8.39M | 0 | 17 | |
| MIGAUSKY GEORGE V | director | 109808 0.0545% | $2.88M | 1 | 1 | <0.0001% |
| Pande Atul | director | 86663 0.043% | $2.28M | 2 | 2 | +99.21% |
$193,151,375 | 134 | 8.18% | $4.43B | |
$224,382,625 | 44 | 27.62% | $4.71B | |
Immunovant, Inc. (IMVT) | $477,065,869 | 34 | 82.05% | $5.29B |
$103,944,213 | 17 | 5.95% | $6.78B | |
$74,605,681 | 14 | 47.06% | $5.1B | |
$57,686,748 | 13 | 21.11% | $5.82B | |
$75,296,863 | 13 | 33.79% | $5.49B | |
$9,976,473 | 12 | 29.52% | $6.71B | |
$91,269,919 | 12 | 12.86% | $5.74B | |
$2,477,801 | 11 | 4.98% | $5.22B | |
$3,073,199 | 10 | 16.77% | $4.95B | |
$35,908,794 | 10 | 126.31% | $5.13B | |
$25,064,843 | 9 | 12.75% | $4.59B | |
$20,499,451 | 9 | 71.54% | $5.92B | |
$55,713,031 | 8 | -0.36% | $5.44B | |
$2,246,813 | 6 | 70.15% | $4.85B | |
$105,414,951 | 5 | 10.07% | $7.58B | |
$41,376,000 | 4 | -12.07% | $6.1B | |
$50,990,767 | 2 | 19.79% | $4.43B |
| Increased Positions | 101 | +58.05% | 9M | +9.59% |
| Decreased Positions | 69 | -39.66% | 10M | -10.06% |
| New Positions | 35 | New | 2M | New |
| Sold Out Positions | 16 | Sold Out | 902,481 | Sold Out |
| Total Postitions | 206 | +18.39% | 96M | -0.47% |
| Fmr Llc | $381,643.00 | 7.33% | 14.73M | -4M | -20.8% | 2025-09-30 |
| Deep Track Capital, Lp | $252,074.00 | 4.84% | 9.73M | +228,845 | +2.41% | 2025-09-30 |
| Vanguard Group Inc | $176,883.00 | 3.4% | 6.83M | -199,128 | -2.83% | 2025-09-30 |
| Armistice Capital, Llc | $151,211.00 | 2.9% | 5.84M | +636,000 | +12.23% | 2025-09-30 |
| Blackrock, Inc. | $148,678.00 | 2.86% | 5.74M | -110,049 | -1.88% | 2025-09-30 |
| Baker Bros. Advisors Lp | $141,414.00 | 2.72% | 5.46M | 0 | 0% | 2025-09-30 |
| T. Rowe Price Investment Management, Inc. | $133,817.00 | 2.57% | 5.16M | -2M | -24.92% | 2025-09-30 |
| Point72 Asset Management, L.P. | $89,184.00 | 1.71% | 3.44M | +105,828 | +3.17% | 2025-09-30 |
| State Street Corp | $74,948.00 | 1.44% | 2.89M | +62,544 | +2.21% | 2025-09-30 |
| Two Seas Capital Lp | $71,564.00 | 1.37% | 2.76M | +509,268 | +22.61% | 2025-09-30 |